Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis.


Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
2021
Historique:
received: 05 01 2021
revised: 09 04 2021
accepted: 10 04 2021
pubmed: 27 4 2021
medline: 31 7 2021
entrez: 26 4 2021
Statut: ppublish

Résumé

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that is characterized by a high heterogeneity in patients' disease course. Patients with bulbar onset of symptoms (b-ALS) have a poorer prognosis than patients with limb onset (l-ALS). However, neuroimaging correlates of the assumed biological difference between b-ALS and l-ALS may have been obfuscated by patients' diversity in the disease course. We conducted Voxel-Based-Morphometry (VBM) and Tract-Based-Spatial-Statistics (TBSS) in a group of 76 ALS patients without clinically relevant cognitive deficits. The subgroups of 26 b-ALS and 52 l-ALS patients did not differ in terms of disease Phase or disease aggressiveness according to the D50 progression model. VBM analyses showed widespread ALS-related changes in grey and white matter, that were more pronounced for b-ALS. TBSS analyses revealed that b-ALS was predominantly characterized by frontal fractional anisotropy decreases. This demonstrates a higher degree of neurodegenerative burden for the group of b-ALS patients in comparison to l-ALS. Correspondingly, higher bulbar symptom burden was associated with right-temporal and inferior-frontal grey matter density decreases as well as fractional anisotropy decreases in inter-hemispheric and long association tracts. Contrasts between patients in Phase I and Phase II further revealed that b-ALS was characterized by an early cortical pathology and showed a spread only outside primary motor regions to frontal and temporal areas. In contrast, l-ALS showed ongoing structural integrity loss within primary motor-regions until Phase II. We therefore provide a strong rationale to treat both onset types of disease separately in ALS studies.

Identifiants

pubmed: 33901988
pii: S2213-1582(21)00118-2
doi: 10.1016/j.nicl.2021.102674
pmc: PMC8099783
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102674

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):9-14
pubmed: 23781974
Nat Rev Neurol. 2013 Dec;9(12):708-14
pubmed: 24217521
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):385-395
pubmed: 31088163
Neurology. 2017 Jun 13;88(24):2302-2309
pubmed: 28500227
Neurology. 2007 Feb 20;68(8):600-2
pubmed: 17310031
J Neurol. 2017 Nov;264(11):2224-2231
pubmed: 28914354
J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):917-924
pubmed: 28710326
PLoS One. 2015 Mar 20;10(3):e0119045
pubmed: 25793718
J Neurol. 2012 Sep;259(9):1848-59
pubmed: 22349938
J Clin Med. 2020 Sep 05;9(9):
pubmed: 32899481
Muscle Nerve. 2009 Aug;40(2):297-304
pubmed: 19609920
Health Qual Life Outcomes. 2020 May 1;18(1):117
pubmed: 32357946
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):216-25
pubmed: 24555884
Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Dec;6(4):213-20
pubmed: 16319024
Neuroimage. 2009 Jan 1;44(1):83-98
pubmed: 18501637
J Neurol Sci. 1999 Oct 31;169(1-2):13-21
pubmed: 10540002
J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):38-44
pubmed: 24336810
J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):53-60
pubmed: 29054917
Neuroimage Clin. 2020;25:102094
pubmed: 31896467
J Neurol. 2013 Nov;260(11):2856-64
pubmed: 23996101
Amyotroph Lateral Scler. 2007 Dec;8(6):343-7
pubmed: 18033592
Neuroimage. 2014 May 15;92:381-97
pubmed: 24530839
Hum Brain Mapp. 2021 Feb 15;42(3):737-752
pubmed: 33103324
Sci Rep. 2019 Dec 27;9(1):20059
pubmed: 31882886
Neuroimage. 2018 Apr 15;170:400-411
pubmed: 28213119
Neuroimage Clin. 2017 Jan 24;14:269-276
pubmed: 28203530
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):638-9
pubmed: 23859502
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Cochrane Database Syst Rev. 2016 Jan 13;(1):CD011145
pubmed: 26760674
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
J Neurol. 2017 Jan;264(1):54-63
pubmed: 27778156
Neurologist. 2004 Sep;10(5):235-49
pubmed: 15335441
Ann Neurol. 2014 Nov;76(5):643-57
pubmed: 25223628
PLoS One. 2018 Apr 16;13(4):e0195821
pubmed: 29659621
Neurology. 2020 Jun 16;94(24):e2592-e2604
pubmed: 32414878
PLoS One. 2014 Aug 18;9(8):e104894
pubmed: 25133577
PLoS One. 2017 Jan 17;12(1):e0168424
pubmed: 28095425
J Comp Neurol. 1997 Dec 8;389(1):34-48
pubmed: 9390758
Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):524-9
pubmed: 26402254
PLoS One. 2009 Sep 22;4(9):e7107
pubmed: 19771164
J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):766-73
pubmed: 23085933
J Neurophysiol. 2004 Aug;92(2):1153-64
pubmed: 15056683
Clin Neurol Neurosurg. 2013 Aug;115(8):1281-7
pubmed: 23266262
PLoS One. 2017 Jun 2;12(6):e0178371
pubmed: 28575122
Brain. 2012 Mar;135(Pt 3):847-52
pubmed: 22271664
Brain. 2011 Apr;134(Pt 4):1211-28
pubmed: 21362631
J Neurol. 2014 Oct;261(10):1961-7
pubmed: 25059391
J Neurol Neurosurg Psychiatry. 2017 May;88(5):369-370
pubmed: 27913627
Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16(1-2):16-23
pubmed: 25292386
Hum Brain Mapp. 2007 Dec;28(12):1430-8
pubmed: 17370339
Lancet Neurol. 2018 May;17(5):423-433
pubmed: 29598923
J Neuroradiol. 2018 Feb;45(1):41-48
pubmed: 28802959
AJNR Am J Neuroradiol. 2012 Jun;33(6):1102-8
pubmed: 22300932
Cereb Cortex. 2016 Aug;26(8):3508-26
pubmed: 27230218
Amyotroph Lateral Scler. 2009 Feb;10(1):47-52
pubmed: 18622772
Neuroimage Clin. 2018 Apr 04;19:122-129
pubmed: 30035009
Hum Brain Mapp. 2009 Nov;30(11):3657-75
pubmed: 19404990
Neuroimage. 2002 Nov;17(3):1429-36
pubmed: 12414282
Neurol Sci. 2005 Jun;26(2):108-16
pubmed: 15995827

Auteurs

Robert Steinbach (R)

Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany. Electronic address: Robert.Steinbach@med.uni-jena.de.

Tino Prell (T)

Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany; Center for Healthy Ageing, Jena University Hospital, Jena.

Nayana Gaur (N)

Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany.

Annekathrin Roediger (A)

Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany.

Christian Gaser (C)

Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany; Center for Healthy Ageing, Jena University Hospital, Jena; Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.

Thomas E Mayer (TE)

Department of Neuroradiology, Jena University Hospital, Jena, Germany.

Otto W Witte (OW)

Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany; Center for Healthy Ageing, Jena University Hospital, Jena.

Julian Grosskreutz (J)

Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany; Center for Healthy Ageing, Jena University Hospital, Jena.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH